HOUSTON, Feb. 6, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
the appointment of James Bucher as
Senior Sales Consultant. In this role, Mr. Bucher will be
responsible for developing sales strategies regarding Soliton's
Rapid Acoustic Pulse ("RAP") device for tattoo removal and other
potential future indications, including improvement in the
appearance of cellulite and keloids (fibrotic scars).
Dr. Chris Capelli, Soliton's
President, CEO and co-founder, commented, "We welcome James and the
opportunity to leverage his expansive experience in leading
strategic sales initiatives within the medical aesthetic device
industry, particularly his work with miraDry and Zeltiq
(Coolsculpting). We believe his insights will be instrumental to
the growth of our business as we advance towards the U.S. limited
launch of our RAP device this year and prior to the hiring of a
permanent head of sales in early 2021."
James Bucher is a forty-year
veteran of the medical device industry, having begun his
post-military career with Coherrent Medical, the past twenty years
in sales and marketing strategy and operations for mid-cap medical
device companies focused on aesthetics. Mr. Bucher most recently
served as the Managing Director of Europe for miraDry, Inc. where he was
responsible for the development, implementation and execution of
the overall European commercialization approach. Prior to joining
miraDry, Mr.Bucher acted as Vice President of Europe, Middle
East and Africa at Zeltiq
Aesthetics, the makers of Coolsculpting acquired by Allergan Plc.
in 2017 for $2.4 billion. Prior
to Zeltiq, Mr. Bucher held various leadership positions in sales
and field operations positions across laser and other medical
device companies, including Reliant Technologies, Iridex and
Radionics. James earned a B.A. degree in History from Gettysburg
College.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to launch its
product in 2020 and the ability of its product to be approved for
the reduction of cellulite and fibrotic scars. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-advances-market-launch-preparation-appoints-james-bucher-as-senior-sales-consultant-300999876.html
SOURCE Soliton, Inc.